Skip to Content
Merck
CN

357R-1

Sigma-Aldrich

TCL1 (EP105) Rabbit Monoclonal Primary Antibody

Synonym(s):

T-cell leukemia/lymphoma protein 1

Sign Into View Organizational & Contract Pricing

About This Item

UNSPSC Code:
12352203

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

biological source

rabbit

antibody form

culture supernatant

antibody product type

primary antibodies

clone

EP105, monoclonal

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate Research Use Only (357R-14-RUO)
vial of 0.1 mL concentrated (357R-14)
vial of 0.5 mL concentrated (357R-15)
vial of 1.0 mL concentrate Research Use Only (357R-16-RUO)
vial of 1.0 mL concentrated (357R-16)
vial of 1.0 mL pre-dilute Research Use Only (357R-17-RUO)
vial of 1.0 mL predilute ready-to-use (357R-17)
vial of 7.0 mL pre-dilute ready-to-use Research Use Only (357R-18-RUO)
vial of 7.0 mL predilute ready-to-use (357R-18)

manufacturer/tradename

Cell Marque®

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:200 (concentrated)

control

follicular lymphoma, tonsil

shipped in

wet ice

storage temp.

2-8°C

visualization

cytoplasmic (tonsil), nuclear (tonsil, follicular lymphoma)

Gene Information

human ... TCL1A(8115)

General description

T-cell leukemia/lymphoma protein 1 (TCL1, TCL1A, p14TCL1) is a 14 kDa product of the TCL1 gene. TCL1 protein is normally found in the nucleus and cytoplasm of lymphoid lineage cells during early embryogenesis. Chromosomal translocations may lead to overexpression of TCL1, resulting in T-cell leukemia and B-cell lymphoma. TCL1 binds to a novel site in the pleckstrin homology (PH) domain, resulting in activation and nuclear translocation of Akt by overexpressed TCL1 which may promote an anti-apoptotic response; this may normally serve to promote growth during development but may lead to malignancy when TCL1 is overexpressed. TCL1 is expressed in differentiated B-cells under both reactive and neoplastic conditions, antigen committed B-cells, and in germinal center B-cells. TCL1 is down-regulated in the latest stage of B-cell differentiation. TCL1 is overexpressed in Burkitt lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, and follicular lymphoma.

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Download the latest released IFU
Note: This IFU may not apply to your specific product lot.

Analysis Note

United States - IVD
Canada - IVD
European Union - IVD
Japan - RUO

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
TCL1 Positive Control Slides, Product No. 357S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Legal Information

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

监管及禁止进口产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000138420
0000117692
0000117691
0000117669
0000117696

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J Roos et al.
Pathobiology : journal of immunopathology, molecular and cellular biology, 69(2), 59-66 (2001-12-26)
TCL1, MTCP1 and TCL1b are three members of a new family of oncogenes that are expressed in T cell leukemias of ataxia telangiectasia patients (T-PLL, T-CLL). TCL1 is located at 14q32.1 and activated by juxtaposition to the alpha/delta-locus at 14q11
Yuri Pekarsky et al.
Hematology/oncology clinics of North America, 18(4), 863-879 (2004-08-25)
Mature leukemias and lymphomas are a heterogeneous group of lymphoproliferative neoplasias characterized by the accumulation of mature lymphocytes in lymph nodes, other lymphoid tissues, and peripheral blood. In this article we discuss molecular mechanisms leading to the pathogenesis of two
Y Pekarsky et al.
Oncogene, 20(40), 5638-5643 (2001-10-19)
The TCL1 locus on human chromosome 14q32.1 is activated in T-cell leukemias by translocations and inversions that juxtapose it to regulatory elements of T-cell receptor genes. We isolated and characterized four genes at this locus, TCL1 and TCL1b (T-cell leukemia/lymphoma
J Takizawa et al.
Japanese journal of cancer research : Gann, 89(7), 712-718 (1998-09-17)
The TCL1 gene was recently cloned as a candidate target within the 14q32.1 breakpoint cluster region observed in T-cell malignancies. We examined the TCL1 gene expression in 21 patients with adult T-cell leukemia (ATL) and 5 cell lines, because ATL
Scott J Rodig et al.
The American journal of surgical pathology, 32(1), 113-122 (2007-12-29)
The distinction between Burkitt (BL) or atypical Burkitt/Burkitt-like lymphomas harboring a MYC translocation (MYC+) and diffuse large B-cell lymphomas (DLBCLs) with high proliferation fractions but without a MYC translocation (MYC-) can be difficult using standard morphologic and immunohistochemical criteria. Recently
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service